Revenue, Collaboration (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2018 USD ($)	Jul. 31, 2014 USD ($) Target	Dec. 31, 2023 USD ($) Target	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaboration [Abstract]
Revenue recognized			$ 10,693	$ 33,674	$ 32,406
Deferred revenue recognized			7,800	33,000	29,100
United Kingdom [Member]
Collaboration [Abstract]
Non-current assets			55,400	43,700
United States [Member]
Collaboration [Abstract]
Non-current assets			1,800	2,700
Genentech [Member]
Collaboration [Abstract]
Aggregate non-refundable fee payment	$ 100,000
Initial upfront payment	50,000
Amount on investigation of new drug filing for clinical trial	$ 50,000
Revenue recognized			10,693	24,469	24,021
Eli Lilly [Member]
Collaboration [Abstract]
Aggregate non-refundable fee payment		$ 45,000
Revenue recognized			0	9,205	0
Number of targets | Target		3
Total deferred revenue		$ 45,000
Deferred revenue recognized			0	9,200	0
GSK [Member]
Collaboration [Abstract]
Revenue recognized			0	0	8,385
Deferred revenue recognized			0	$ 0	$ 8,400
Transaction price			$ 27,800
GSK [Member] | Maximum [Member]
Collaboration [Abstract]
Number of targets | Target			4